MOR acquires CNST for $34/sh cash—a 68% premium to yesterday’s close—in deal valued at $1.7B: https://finance.yahoo.com/news/morphosys-acquire-constellation-pharmaceuticals-112500240.html Concurrently, MOR inked a multifaceted financing deal with Royalty Pharma (RPRX): https://finance.yahoo.com/news/morphosys-acquire-constellation-pharmaceuticals-112500240.html .